Pretax income is the income that a company earns before paying income taxes. Athira Pharma's pretax income for the
three
months ended in Dec. 2024 was $-15.00 Mil.
Its pretax income for the trailing twelve months (TTM) ended in Dec. 2024 was $-96.94 Mil.
Athira Pharma's pretax margin was %.
Athira Pharma Pre-Tax Income Historical Data
The historical data trend for Athira Pharma's Pre-Tax Income can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Athira Pharma's Pre-Tax Income
For the Biotechnology subindustry, Athira Pharma's Pre-Tax Income, along with its competitors' market caps and Pre-Tax Income data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Athira Pharma's Pre-Tax Income Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Athira Pharma's Pre-Tax Income distribution charts can be found below:
* The bar in red indicates where Athira Pharma's Pre-Tax Income falls into.
Pre-Tax Income for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-96.94 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Athira Pharma (NAS:ATHA) Pre-Tax Income Explanation
Athira Pharma's Pretax Margin for the quarter that ended in Dec. 2024 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Athira Pharma Pre-Tax Income Related Terms
Thank you for viewing the detailed overview of Athira Pharma's Pre-Tax Income provided by GuruFocus.com. Please click on the following links to see related term pages.
Athira Pharma Inc is a late clinical-stage biopharmaceutical company focused on developing small molecules engineered to restore neuronal health and slow neurodegeneration. Its pipeline candidates are; Fosgonimeton (ATH-1017) is a small molecule drug candidate designed to enhance the activity of the neurotrophic hepatocyte growth factor (HGF) system; ATH-1020 a novel, orally available, next-generation small molecule drug candidate designed to positively modulate the neurotrophic HGF system; ATH-1105 is a novel, orally available, next-generation, small molecule drug candidate designed to positively modulate the neurotrophic HGF system.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
ATHA has been successfully added to your 